Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule

DGAP-News: Medios AG / Key word(s): Contract/Personnel
Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule
01.08.2022 / 10:45
The issuer is solely responsible for the content of this announcement.

Press release

Medios AG: Contract of CEO Matthias Gaertner extended ahead of schedule

Berlin, August 01, 2022 – The Supervisory Board of Medios AG ("Medios") and the Chief Executive Officer (CEO) Matthias Gaertner have agreed to extend the existing Executive Board contract prematurely until January 31, 2025. Matthias Gaertner has been a member of the Executive Board since September 2015 and CEO since January 2021. As a result, Medios relies on continuity and stability in the Company's management body.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: "Matthias Gaertner has been a member of the Management Board for almost seven years and has successfully headed Medios AG since January 2021. Under his leadership, the Company has grown enormously and become more profitable. We are very pleased to have won him over for another term as CEO and that we can continue our successful and trusting cooperation in the coming years. In this way, we create continuity and ensure a sustainable orientation in the management of the Company."

Matthias Gaertner, CEO of Medios AG: "I would like to express my sincere thanks for the trust that has been placed in me and I am convinced that we will be able to continue to successfully drive forward the profitable growth of Medios AG together in the future. I am very much looking forward to this task and to the further cooperation with the Supervisory Board and my colleagues on the Executive Board." 

Important events for Medios AG in the 2022 financial year:

 -------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company and is included in the SDAX selection index. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact

Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestrasse 9 | 10557 Berlin
P +49 30 232 566 800
c.nickolaus@medios.ag

www.medios.ag

Anna Höffken
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg
P +49 40 609 186 34
anna.hoeffken@kirchhoff.de

www.kirchhoff.de
 

Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.

01.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de